This MoCo biotech just raised another $20M to get its superbug-killing therapy through the clinic
Gaithersburg ’s Adaptive Phage Therapeutics Inc. has raised another $20 million in funding, less than a year after securing nearly $41 million to advance its therapy for superbugs.
The new funding brings the Series B total to $61 million, allowing the company to accelerate clinical trials for two programs: pr osthetic joint infection and diabetic foot osteomyelitis, in which soft tissue infections can spread to the bone and require amputation. Adaptive Phage is now enrolling patients in both studies…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Sara Gilgore Source Type: news
More News: Biotechnology | Clinical Trials | Diabetes | Endocrinology | Funding | Health Management | Infectious Diseases | Osteomyelitis | Superbugs